Related Experiment Video
Updated: Oct 13, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Chronic alanine aminotransferase elevation in people with HIV: Time trends over 22 years and genetic predisposition
Noemi R Simon1,2, Carlotta Mondoka3,4, Christian W Thorball5,6
1Infectious Diseases Service and University Center for Internal Medicine, Kantonsspital Baselland, University of Basel, Bruderholz, Switzerland.
Introduction:
Chronic elevation of alanine aminotransferase (cALT) is common in people with HIV. Published reports on cALT prevalence time trends have not been uniform. It is unknown whether genetic background is associated with cALT in people with HIV.
Methods:
cALT was defined as ALT levels (male, >50 U/L, female, >35 U/L) at ≥2 consecutive, 6-monthly per protocol Swiss HIV Cohort Study (SHCS) visits. We calculated cALT prevalence plus trends in time-updated clinical and HIV-related cALT risk factors per calendar year in SHCS participants without viral hepatitis co-infection. In cALT cases and matched controls, we obtained uni- and multivariable odds ratios (ORs) for cALT, adjusting additionally for a polygenic risk score (PGS) associated with transaminase levels in the general population.
Results:
Between 2002 and 2023, 8'909 SHCS participants contributed 203'832 ALT values obtained per protocol, and 8'414 cALT events occurred. The yearly cALT prevalence increased significantly (p < 0.001) from 7.5% (95% confidence interval, 6.3%-8.9%) in 2002 to the highest level of 10.1% (9.1%-11.1%) in 2005, followed by a significant (p < 0.001) decline to 5.3% (4.8%-5.9%) in 2018, with stable rates thereafter (p = 0.280). An increased multivariable cALT-OR was noted for obesity (OR = 2.84; 1.99-4.07), for 6-12-month exposure to non-nucleoside reverse transcriptase inhibitors (OR = 2.09; 1.09-4.03) and tenofovir disoproxil fumarate (OR = 1.99; 1.15-3.46). Participants with unfavourable genetic background (top vs. bottom quintile of PGS) had a multivariable-adjusted cALT-OR of 4.44 (3.09-6.39).
Conclusion:
cALT prevalence has decreased by almost half in people with HIV in Switzerland since 2005. Unfavourable genetic background is a strong independent risk factor for cALT.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis II: Pathophysiology
Drug Toxicity: Risk factors
Amebiasis
